Chinese medical devices maker,
Mindray Medical International Ltd
), recently announced that it will present its products at the
American Association for Clinical Chemistry's 2012 Clinical Lab
Expo. The exhibition will be held at Los Angeles, California, from
July 17 to July 19.
The sophisticated and high-profile domain of the Clinical Lab
Expo attracts reputed clinical laboratory professionals. Mindray is
enthused about the opportunity to participate in the conference. It
will use the opportunity to display its complete range of in-vitro
diagnostic products as well as new products such as BS-2000 Auto
Biochemistry Analyzer and EH-2050B Plus Automatic Urine Sediment
The BS-2000 modular system is the company's fastest biochemistry
analyzer. The output range is 2,000 photometric tests for single
modules, to 4,400 for dual modules with electrolyte tests. Given
its high speed and methodological traceability, the product will be
beneficial for hospital and clinical laboratories with high sample
volumes, adding to versatility.
Mindray believes that BS-2000 has a high level of efficiency,
automation and scalability. It also boasts of the easy
consolidation of the product with its future offerings.
The Automatic Urine Sediment Analyzer EH-2050B for comprehensive
urinalysis of patients is for automatic detection of the presence
of red blood cells and other elements in the patients' urine
samples. Additionally, EH-2050B can be used in conjunction with
various urinary dry-chemistry analyzers. The subsequent data from
such analysis can help in developing an integrated urinalysis
report of the patient.
Mindray is a bellwether in the Chinese MedTech industry with a
solid international presence. A key distinction with domestic
competitors is that the majority of Mindray's products have CE Mark
and/or Food and Drug Administration (FDA) clearance.
Mindray remains committed to innovative and high-quality product
development in order to deliver high-performance towards consumer
demand. The company maintains a decent product pipeline and brings
out several new products each year. New products contribute in a
major way to Mindray's revenues.
The company has entered the premium segment globally, where its
competitive advantage is still unclear. Also, on the negative side,
health care reforms in China and the U.S. may reduce demand for
Mindray's products. Competition is fierce and could lead to price
erosion over time.
Mindray's competitors in different niche segments include GE
Healthcare, a part of
), Phillips Healthcare under
). Our Neutral recommendation is supported by a short-term Zacks #3
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis
KONINKLIJKE PHL (PHG): Free Stock Analysis
SIEMENS AG-ADR (SI): Free Stock Analysis Report
To read this article on Zacks.com click here.